Published in final edited form as:

J Diabetes. 2014 May ; 6(3): 251–259. doi:10.1111/1753-0407.12093.

CDKAL1 and HHEX are associated with type-2 diabetes-related traits among Yup'ik people

Yann C. KLIMENTIDIS¹, Dominick J. LEMAS², Howard H. WIENER³, Diane M. O'BRIEN⁴, Peter J. HAVEL^{5,6}, Kimber L. STANHOPE^{5,6}, Scarlett E. HOPKINS⁴, Hemant K. TIWARI⁷, and Bert B. BOYER^{4,*}

¹Mel and Enid Zuckerman College of Public Health, Division of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, 85724

²Department of Pediatrics, Section of Neonatology, University of Colorado Denver, Aurora, CO 80045

³Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294

⁴Center for Alaska Native Health Research, Institute of Arctic Biology, University of Alaska Fairbanks, Fairbanks, AK 99775

⁵Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616

⁶Department of Nutrition, University of California, Davis, Davis, CA 95616

⁷Section on Statistical Genetics, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294

Abstract

Background: Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) associated with type-2 diabetes (T2D), mainly among individuals of European ancestry. We examined the frequency of these SNPs and their association with T2D-related traits in an Alaska Native study population with a historically low prevalence of T2D. We also investigated whether dietary characteristics that may protect against T2D, such as n-3 polyunsaturated fatty acid (n-3 PUFA) intake, modify these associations.

Methods: In 1,144 Yup'ik people, we examined 17 SNPs repeatedly identified in GWAS for individual and cumulative associations with T2D-related traits. Cumulative associations were evaluated using a genetic risk score (GRS) calculated by summing risk alleles. Associations were tested for interactions with sex, BMI, and n-3 PUFA intake.

Results: The rs7754840 SNP in *CDKAL1* is significantly associated with HbA_{1c} (p=0.00091). The rs5015480 SNP near *HHEX* is significantly associated (in opposite direction to that in

* **Corresponding author:** Yann C. Klimentidis, PhD, Mel and Enid Zuckerman College of Public Health, Division of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, 85724. Phone: 520-621-1047, yann@email.arizona.edu.

Significant findings of the study: We examine and compare the frequency of T2D-associated SNPs in Yup'ik people. SNPs in *CDKAL1* and *HHEX* are found to be associated with glycemic traits in this sample. Associations are not modified by BMI or dietary n-3 PUFA intake.

What this study adds: This is the first study to examine the frequency of T2D SNPs in an Alaska Native population, which has a historically low prevalence of T2D. We examine associations between SNPs and glycemic traits, and interactions with BMI and n-3 PUFA intake.

DISCLOSURE

The authors have no potential conflict of interest to report.

Europeans) with a combined fasting glucose (FG) and HbA_{1c} measure ($p=0.00046$) and with HOMA-B ($p=0.0014$). The GRS is significantly associated with FG and combined FG & HbA_{1c} only when the *HHEX* SNP is dropped from the GRS. Associations are not modified by BMI or n-3 PUFA intake.

Conclusion: Our results highlight the potential importance of *CDKAL1* and *HHEX* in glucose homeostasis in this Alaska Native population with a low prevalence of T2D, and suggest that these loci should be examined in greater detail in this population.

Keywords

Alaska Native; CANHR; type-2 diabetes SNPs; glycemic traits

INTRODUCTION

Type-2 diabetes (T2D) is a major health concern, often disproportionately affecting Native American populations.^{1–3} Prior to the 1980s, epidemiological studies demonstrated that T2D among Alaska Native people was a rare condition.⁴ Despite data suggesting that the prevalence of T2D is increasing among coastal Alaska Native communities, Yup'ik people from Southwest Alaska continue to demonstrate a T2D prevalence (4 to 6%) that is lower compared to the overall US population (8%), and may be independent of obesity status.^{1,2,5,6} The mechanisms that allow Yup'ik people to carry excess body fat without developing T2D at the same rate as other populations may involve dietary and genetic factors.

Several studies suggest that genetic factors partially underlie T2D and related traits.^{7,8} Genome-wide association studies (GWAS) for T2D and related traits have been performed mainly among individuals of European descent.^{9–11} Subsequent studies have found evidence of consistent associations of these SNPs across populations^{12–14}, although associations at some loci, such as *TCF7L2*, do not appear to be generalizable.¹⁵ Currently, little is known regarding the frequency of these SNPs among Alaska Native people, and whether they are associated with T2D traits.

Epidemiologic studies have reported a lower prevalence of impaired glucose tolerance and T2D in populations consuming large amounts of n-3 PUFAs found mainly in fish and marine mammals.¹⁶ Yup'ik people have an unusually high variability in n-3 PUFA intake, because fish and marine mammals are an important part of the traditional diet, but adherence to this diet is highly variable.^{17,18} Consumption of n- PUFAs may contribute to the low prevalence of T2D in this group,¹⁹ and genetic factors may mediate this association.

Understanding the genetic mechanisms and dietary interactions underlying T2D pathophysiology will require knowledge regarding how loci identified in T2D GWAS are associated with specific T2D-related quantitative traits. Previous studies suggest considerable overlap of loci associated with T2D and related quantitative traits,^{10,20,21} and that distinct genetic factors underlie each of these quantitative traits.^{22,23}

In this study, we determine the extent to which 17 T2D-associated SNPs identified in the first wave of GWAS and confirmed in recent GWAS meta-analyses, are polymorphic, are associated with glycemic traits, and interact with n-3 PUFA intake in a sample of 1,144 Yup'ik people from a population with a historically low prevalence of T2D..

METHODS

Study sample

Through the Center for Alaska Native Health Research (CANHR), Yup'ik participants were recruited in 11 southwest Alaska communities to participate in a study examining genetic, behavioral, and dietary factors underlying metabolic traits. The sample used here consists of 1,144 non-pregnant self-identified Yup'ik people between the ages of 14 and 94. Summary statistics regarding family structure among participants were calculated using PEDINFO in the Statistical Analysis for Genetic Epidemiology (S.A.G.E., 2009) software. The sample consists of 49 founders, 969 non-founders, and 123 singletons. There were 195 pedigrees with a mean size of 11.44 individuals (range, 1-894) and 696 sibships with a mean size of 1.39 individuals (range, 1-9). The age distribution in this study resembles the age distribution among eligible participants, according to the 2000 US Census data. Informed consent was obtained from all participants using protocols approved by the University of Alaska Institutional Review Board, the National and Alaska Area Indian Health Service Institutional Review Boards, and the Yukon Kuskokwim Health Corporation Human Studies Committee.

Phenotypic and dietary measurements

Height and weight measurements were obtained by trained staff using protocols from the NHANES (National Health and Nutrition Examination Survey) III Anthropometric Procedures Manual,²⁴ as previously described.⁵ Fasting insulin (FI) was assayed with radioimmunoassay kit using an I¹²⁵-iodinated insulin tracer, anti-human insulin specific antibody, and human insulin standards from Linco Research where the intra- and inter-assay variations were 5.8% and 10.2%, respectively. Fasting blood glucose (FG) was measured on a Cholestech LDX analyzer, and glycosylated hemoglobin (HbA_{1c}) was measured on a Bayer HbA_{1c} DCA 2000+ analyzer (Bayer AG, Leverkusen, Germany). We calculated HOMA-IR (homeostatic model assessment of insulin resistance) as the product of FG and FI divided by 22.5, and HOMA-B (homeostatic model assessment of beta-cell function) as $(FI * 360) / (FG - 63)$.²⁵ Finally, we defined a continuous variable called 'FG & HbA_{1c}' based on previous studies indicating that combined information from FG and HbA_{1c} is a reliable predictor of developing T2D.^{26,27} The FG & HbA_{1c} variable was calculated by first standardizing each variable to have a standard deviation of 1, then using the mean of the two standardized variables. Data on diabetes-related medications (metformin, glyburide, pioglitazone) were obtained through self-report at the time participants were enrolled in the study, and extracted from the Yukon Kuskokwim Health Corporation medical records by a trained nurse. Long-chain n-3 PUFA intake was assessed using the nitrogen stable isotope ratio (¹⁵N/¹⁴N) of red blood cells, as previously described.^{18,28}

Genotypes

Genes selected for this study included those identified in the first wave of GWAS for T2D,²⁹⁻³² and also replicated in a meta-analysis.¹⁰ Specific SNPs within or near each gene were selected based on which has been associated with T2D in more than one GWAS, as of June, 2011. Genotyping was conducted at the Broad Institute (Cambridge, MA) using a Sequenom iPLEX platform.³³ The *FTO* SNP (rs9939609) was previously investigated for association with body composition traits in this sample.³⁴ We excluded SNPs with > 10% missing frequency or a minor allele frequency < 1%. Allele frequencies and deviations from Hardy-Weinberg equilibrium were evaluated using MENDEL software,³⁵ accounting for family structure. We compared allele frequencies in this sample to those in five HapMap reference populations.³⁶

Genetic risk score

A genetic risk score (GRS) was calculated for all individuals with at least six non-missing genotypes for the fourteen SNPs considered. Risk alleles were defined as those which are positively associated with T2D risk in GWAS. The sum of risk alleles was divided by the number of non-missing genotypes, to account for missing genotypes. We also used a weighted GRS, with weights corresponding to published T2D odds ratios.¹⁰

Statistical analyses

Linear models were fit to each phenotype using the following covariates: age, sex, BMI, medication use, and community location. We ran analyses with and without BMI as a covariate to evaluate the extent to which significant associations with T2D-related traits were mediated by obesity. The community location variable is based on the second principal component from a principal components analysis (PCA) of 4,108 autosomal markers, as previously described,²⁸ and corresponds to the proximity of each community to the coast. It is included as a covariate in the analyses to control for population stratification. The first component from this PCA had no obvious systematic structure, as previously described.³⁷ As a sensitivity analysis, we examined the effect of controlling for the first PC on our main findings. The distributions of residuals from linear models were examined for normality, and Box-Cox transformations³⁸ and extreme outlier removal were implemented for each phenotype that deviated from the normality assumption.

We accounted for within-pedigree correlation using the linear mixed effects model (LME) implemented in the 'lme4' function in the *coxme* package (<http://cran.r-project.org/web/packages/coxme/index.html>)³⁹ to test the association between each phenotype and each SNP, using an additive genetic model. We tested the cumulative association of these SNPs with each phenotype using the GRS, including the same covariates listed above. We also examined interactions with sex, BMI, and n-3 PUFA intake. We used a Bonferroni correction for multiple testing (14 tests) in the single SNP analyses ($\alpha=3.57 \times 10^{-3}$).

RESULTS

Descriptive Statistics

The sample consists of 540 males and 604 females. Mean phenotypic values for the entire sample and for each sex are listed in Table 1. Females have significantly higher BMI, FG, FI, HOMA-IR, and HOMA-B, and significantly lower FG. Thirteen individuals reported taking T2D-related medication. After excluding outliers (FG>215, HbA_{1c}>9) and individuals taking medication, we find that 0.97% of individuals have a FG above 125 mg/dL, 1.3% of individuals have an HbA_{1c} equal or greater than 6.5%, 20% have a FG between 100 and 125 mg/dL, and 24% of individuals have an HbA_{1c} between 5.7 and 6.4%.

Two of the 17 SNPs (rs10923931-*NOTCH2* and rs7578597-*THADA*) had an extremely low MAF (<0.01), and one SNP had a missing rate > 10% (rs1801282 – *PPARG*), thus precluding them from analyses. Our analysis therefore included a total of 14 SNPs. The frequency of the risk allele for each SNP in this sample and in selected HapMap populations is listed in Table 2. The allele frequencies in Yup'ik people do not differ appreciably from that of geographically close populations (e.g. CHB). All SNPs are in Hardy Weinberg equilibrium after correction for multiple testing ($p > 0.0036$).

Association of individual SNPs and n-3 PUFA with phenotypes

We find that n-3 PUFA intake is positively and significantly associated with HbA_{1c} ($p=0.02$), after adjusting for covariates.

We find that 10 of the 14 SNPs are associated with increased HbA_{1c} and FI in a direction consistent with GWAS findings for T2D. 9 out of 14 SNPs are associated with FG, FI, HOMA-IR, and the combined FG & HbA_{1c} measure in a direction consistent with T2D GWAS. 8 out of 14 T2D GWAS risk alleles are associated with a decrease in HOMA-B (see Table 3).

The only statistically significant SNP associations, after correction for multiple testing, are between rs7754840 (*CDKALI*) and HbA_{1c} ($p=9.1 \times 10^{-4}$), and between rs5015480 (*HHEX*) and the combined FG & HbA_{1c} measure ($p=4.6 \times 10^{-4}$), as well as with HOMA-B ($p=1.4 \times 10^{-3}$) (see Table 3). These associations do not appear to be driven principally by BMI, as the strength of association differs minimally upon adjusting for BMI (see Table 3). Controlling for the 1st PC very slightly attenuated the strength of both associations, but results were still statistically significant. Interestingly, the associations with the SNP in *HHEX* are in the opposite direction compared to GWAS findings. The present analysis revealed that the T allele is associated with higher trait values (and lower HOMA-B), while in GWAS, the C allele is associated with greater T2D risk. Variation at rs7754840 explains approximately 0.8% of variation in HbA_{1c}, and variation at rs5015480 explains approximately 0.8% of variation in FG & HbA_{1c} and HOMA-B. The association between the *MTNR1B* SNP (rs10830963) and HOMA-B is marginally significant ($p=6.4 \times 10^{-3}$).

We found no evidence that associations were significantly modified by BMI, sex, or n-3 PUFA intake (see Supplementary Table 1-3). Based on a previous study that found that the associations between both *CDKALI* and *HHEX* variants and T2D risk were stronger in females than males⁴⁰, we examined associations stratified by sex. The association between rs7754840 (*CDKALI*) and HbA_{1c} is significant in females ($p=0.00053$), but not in males ($p=0.35$). The p-value for the interaction of this SNP and sex is nominally significant ($p=0.013$).

Association of T2D GRS with phenotypes

The T2D GRS is positively associated with all phenotypes, although none of the associations are statistically significant (see Table 3). Since the associations with the *HHEX* SNP were in the opposite direction in this sample, compared to GWAS, we computed a GRS excluding this SNP. We find that this GRS is positively and significantly associated with FG & HbA_{1c} ($p=0.014$) and with FG ($p=0.021$). The proportion of variance in these traits explained by this modified GRS is 1.2% or less. Results did not improve or change significantly with a weighted GRS. Using a risk score without *CDKALI* (and without *HHEX*), the p-value for association increases to 0.11 for FG & HbA_{1c} and to 0.055 for FG.

We examined risk scores in which only nominally significant ($p<0.05$) SNPs in a consistent direction are included in the score. For FG, a risk score comprised of *IGF2BP2* and *MTNR1B* is nearly significantly associated with fasting glucose ($p=0.05$). For the other traits, there are either no nominally significant associations with any SNPs, or the only significant SNP (in a consistent direction) is *CDKALI* or *MTNR1B*.

Using the GRS without the *HHEX* SNP, we find no evidence that associations between the GRS and FG and FG & HbA_{1c} are modified by sex, BMI, or n-3 PUFA intake.

DISCUSSION

We examined whether SNPs identified in T2D GWAS among individuals of European descent are associated with T2D-related traits among Yup'ik people who have a historically low prevalence of T2D. The prevalence of prediabetes (defined as HbA_{1c} greater than 5.6

but less than or equal to 6.5, or FG greater than 99 but less than 126) in this sample of Yup'ik people was relatively low (22%), compared to 35% in the adult US population.⁴¹

Variation in *CDKALI* (rs7754840) was significantly associated with HbA_{1c}. This SNP is located within intron 5 of the *CDKALI* (CDK5 regulatory subunit associated protein 1-like 1) gene. *CDKALI* variants have been found to be associated with reduced beta-cell glucose sensitivity and reduced insulin secretion.^{42,43} A GWAS for HbA_{1c} among normoglycemic Koreans identified *CDKALI* as most strongly associated with HbA_{1c},⁴⁴ and a study among healthy Japanese men found an association between *CDKALI* and HbA_{1c}.⁴⁵ As previously reported in a cohort of Korean individuals,⁴⁰ we find that this association is stronger among females than males.

Variation near *HHEX* (rs5015480) was significantly associated with FG & HbA_{1c} and HOMA-B. This SNP is located upstream of the *HHEX* (hematopoietically expressed homeobox) gene which has been found to be involved in ventral pancreatic development by controlling the proliferation rate of endodermal cells.⁴⁶ This SNP was previously found to be associated with decreased insulin response and beta-cell glucose sensitivity.⁴⁷ Both *CDKALI* and *HHEX* variants were strongly associated with T2D and insulin secretion in several Southeast Asian cohorts and among Pima Indians, respectively.^{54,55} Our finding that the risk allele for the *HHEX* SNP as identified in GWAS corresponds to the “protective” allele in this sample is not uncommon in genetic studies,⁴⁸ and may be attributed to population-unique linkage-disequilibrium patterns, or that the identified SNP is likely not the causal variant. The marginally significant association between rs10830963 in *MTNR1B* (melatonin receptor 1B) and HOMA-B is consistent with previous findings showing that variation in *MTNR1B* is associated with HOMA-B and other insulin secretion measures.^{49–51} *MTNR1B* is expressed in pancreatic islets, and has been implicated in the regulation of circadian rhythms and insulin secretion.^{52,53}

Finally, our analysis revealed the GRS without the *HHEX* SNP was significantly associated with FG and FG & HbA_{1c}, although these associations appear to be driven in large part by the associations with *CDKALI*.

The strengths of this study include detailed phenotypic measurements in a population with a historically low prevalence of T2D and highly variable PUFA intake. However, there are limitations that should be noted. Measures of HbA_{1c} can partly reflect other hematological traits such as hemoglobinopathies,⁵⁶ therefore potentially confounding associations. Secondly, we have no estimate of total caloric or fat intake in the entire sample to include as a covariate in associations involving n-3 PUFA intake, making it difficult to interpret our finding of a positive association between n-3 PUFA intake and HbA_{1c}. For a subset of participants (n=515), total energy and percentage fat intake (% of total calories) data from 24 Hour Recall was available. Within this subset, the association between n-3 PUFA intake and HbA_{1c} is unchanged upon including total energy intake as a covariate. However, upon including % fat intake as a covariate, the association is no longer statistically significant (data not shown), suggesting that additional work is needed to understand the relationship between n-3 PUFA intake and T2D traits.

It should be noted that the discovery of additional T2D susceptibility variants has continued in recent years, with the total number of confirmed SNPs up to approximately 65.²⁰ SNPs included in our study were identified in the first wave of GWAS meta-analysis and may be those with relatively larger effect sizes. Nevertheless, we acknowledge that there are likely hundreds or thousands of variants implicated in T2D. Our results show that Yup'ik study participants have a low prevalence of prediabetes relative to other populations, and that *CDKALI* and *HHEX* variants are associated with FG and HbA_{1c}. Future studies should fully

characterize variation in the regions surrounding these genes in an effort to elucidate how the molecular mechanisms underlying these phenotypes are mediated by genetic variation and interact with lifestyle and behavioral factors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases Awards R01-DK074842 (PI: B.B.B.), and R01-DK074842-02S1 (PI: B.B.B.); and by the National Center for Research Resources and the National Institute of General Medical Sciences Awards P20RR016430 (PI: B.B.B.). The contents are the responsibility of the authors and do not necessarily represent the views of the National Institutes of Health. The authors thank the community field research assistants who helped with recruitment and data collection, and all study participants and their communities.

REFERENCES

1. Narayanan ML, Schraer CD, Bulkow LR, Koller KR, Asay E, Mayer AM, et al. Diabetes prevalence, incidence, complications and mortality among Alaska Native people 1985-2006. *International Journal Of Circumpolar Health*. 2010; 69:236–52. [PubMed: 20501061]
2. Carter EA, MacCluer JW, Dyke B, Howard BV, Devereux RB, Ebbesson SOE, et al. Diabetes mellitus and impaired fasting glucose in Alaska Eskimos: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. *Diabetologia*. 2006; 49:29–35. [PubMed: 16369773]
3. Knowler WC, Bennett PH, Hamman RF, Miller M. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. *American Journal of Epidemiology*. 1978; 108:497–505. [PubMed: 736028]
4. Schraer CD, Risica PM, Ebbesson SO, Go OT, Howard BV, Mayer AM. Low fasting insulin levels in Eskimos compared to American Indians: are Eskimos less insulin resistant? *International Journal Of Circumpolar Health*. 1999; 58:272–80. [PubMed: 10615832]
5. Boyer BB, Mohatt GV, Plaetke R, Herron J, Stanhope KL, Stephensen C, et al. Metabolic syndrome in Yup'ik Eskimos: the Center for Alaska Native Health Research (CANHR) Study. *Obesity*. 2007; 15:2535–40. [PubMed: 18070741]
6. Diabetes Section. 2011. 2009 Annual BRFSS Report[Internet]. http://dhss.alaska.gov/dph/Chronic/Documents/brfss/pubs/BRFSS09_FullReport.pdf
7. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD. Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. *Diabetologia*. Oct.1987 30:763–8. [PubMed: 3428496]
8. Mills GW, Avery PJ, McCarthy MI, Hattersley AT, Levy JC, Hitman GA, et al. Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. *Diabetologia*. 2004; 47:732–8. [PubMed: 15298351]
9. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nat Genet*. May.2008 40:638–45. [PubMed: 18372903]
10. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet*. Jul.2010 42:579–89. [PubMed: 20581827]
11. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet*. Feb. 2010 42:105–16. [PubMed: 20081858]
12. Waters KM, Stram DO, Hassanein MT, Le Marchand L, Wilkens LR, Maskarinec G, et al. Consistent association of type 2 diabetes risk variants found in europeans in diverse racial and ethnic groups. *PLoS Genet*. Aug.2010 6

13. Lewis JP, Palmer ND, Hicks PJ, Sale MM, Langefeld CD, Freedman BI, et al. Association analysis in african americans of European-derived type 2 diabetes single nucleotide polymorphisms from whole-genome association studies. *Diabetes*. Aug.2008 57:2220–5. [PubMed: 18443202]
14. Lin Y, Li P, Cai L, Zhang B, Tang X, Zhang X, et al. Association study of genetic variants in eight genes/loci with type 2 diabetes in a Han Chinese population. *BMC Med Genet*. 2010; 11:97. [PubMed: 20550665]
15. Yan Y, North K, Heiss G. Transcription Factor 7-Like 2 (TCF7L2) polymorphism and context-specific risk of impaired fasting glucose in African American and Caucasian adults: the atherosclerosis risk in communities (ARIC). *Diabetes*. 2010; 2:371–7.
16. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review. *Journal of the American Dietetic Association*. 2005; 105:428–40. [PubMed: 15746832]
17. Johnson JS, Nobmann ED, Asay E, Lanier AP. Dietary intake of Alaska Native people in two regions and implications for health: the Alaska Native Dietary and Subsistence Food Assessment Project. *International Journal Of Circumpolar Health*. 2009; 68:109–22. [PubMed: 19517871]
18. O'Brien DM, Kristal AR, Jeannet MA, Wilkinson MJ, Bersamin A, Luick B. Red blood cell $\delta 15N$: a novel biomarker of dietary eicosapentaenoic acid and docosahexaenoic acid intake. *The American journal of clinical nutrition*. 2009; 89:913–9. [PubMed: 19176727]
19. Makhoul Z, Kristal AR, Gulati R, Luick B, Bersamin A, O'Brien D, et al. Associations of obesity with triglycerides and C-reactive protein are attenuated in adults with high red blood cell eicosapentaenoic and docosahexaenoic acids. *European Journal of Clinical Nutrition*. 2011; 65:808–17. [PubMed: 21427737]
20. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nature genetics*. Sep.2012 44:981–90. [PubMed: 22885922]
21. Scott R, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nature genetics*. Sep.2012 44:991–1005. [PubMed: 22885924]
22. Simonis-Bik AMC, Eekhoff EMW, Diamant M, Boomsma DI, Heine RJ, Dekker JM, et al. The heritability of HbA1c and fasting blood glucose in different measurement settings. *Twin research and human genetics the official journal of the International Society for Twin Studies [Internet]*. 2008; 11:597–602.
23. Snieder H, Sawtell PA, Ross L, Walker J, Spector TD, Leslie RD. HbA(1c) levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. *Diabetes*. 2001; 50:2858–63. [PubMed: 11723071]
24. Lohman, TG.; Roche, AF.; Martorell, R. Anthropometric Standardization Reference Manual. In: Lohman, T.; Roche, A.; Martorell, R., editors. *Medicine & Science in Sports & Exercise*. 1988. p. 177
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. Jul.1985 28:412–9. [PubMed: 3899825]
26. Sato KK, Hayashi T, Harita N, Yoneda T, Nakamura Y, Endo G, et al. Combined Measurement of Fasting Plasma Glucose and A1C Is Effective for the Prediction of Type 2 Diabetes. *Diabetes Care*. 2009; 32:644–6. [PubMed: 19131461]
27. Ko GT, Chan JC, Tsang LW, Cockram CS. Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. *Diabetes Care*. 2000; 23:1770–3. [PubMed: 11128350]
28. Lemas DJ, Wiener HW, O'Brien DM, Hopkins S, Stanhope KL, Havel PJ, et al. Genetic polymorphisms in carnitine palmitoyltransferase 1A gene are associated with variation in body composition and fasting lipid traits in Yup'ik Eskimos. *Journal Of Lipid Research*. 2011; 53:175–84. [PubMed: 22045927]
29. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature*. 2007; 445:881–5. [PubMed: 17293876]

30. Saxena R, Voight BF, Lyssenko V, Burt NP, De Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science*. Jun 1.2007 316:1331–6. [PubMed: 17463246]
31. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. *Nature Genetics*. 2007; 39:770–5. [PubMed: 17460697]
32. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science*. 2007; 316:1336–41. [PubMed: 17463249]
33. Tang K, Fu D-J, Julien D, Braun A, Cantor CR, Köster H. Chip-based genotyping by mass spectrometry. *Proceedings of the National Academy of Sciences of the United States of America*. 1999; 96:10016–20. [PubMed: 10468554]
34. Lemas DJ, Klimentidis YC, Wiener HH, O'Brien DM, Hopkins SE, Allison DB, et al. Obesity polymorphisms identified in genome-wide association studies interact with n-3 polyunsaturated fatty acid intake and modify the genetic association with adiposity phenotypes in Yup'ik people. *Genes and nutrition*. 2013 In Press.
35. Lange K. Mendel version 4.0: a complete package for the exact genetic analysis of discrete traits in pedigree and population data sets. *American Journal of Human Genetic*. 2001; 69:A1886.
36. The International HapMap Consortium. The International HapMap Project. *Nature*. 2003; 426:789–96. [PubMed: 14685227]
37. Aslibekyan S, Vaughan L, Wiener H, Lemas D, Klimentidis Y, Havel P, et al. Evidence for novel genetic loci associated with metabolic traits in Yup'ik people. *Am J Hum Biol*. 2013 In Press.
38. Box GEP, Cox DR. An Analysis of Transformations. *Journal of the Royal Statistical Society Series B Methodological*. 1964; 26:211–52.
39. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2011. <http://www.R-project.org>
40. Ryoo H, Woo J, Kim Y, Lee C. Heterogeneity of genetic associations of CDKAL1 and HHEX with susceptibility of type 2 diabetes mellitus by gender. *European journal of human genetics* EJHG. 2011; 19:672–5. [PubMed: 21368910]
41. CDC. National Diabetes Fact Sheet. 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. 2011
42. Chistiakov DA, Potapov VA, Smetanina SA, Bel'chikova LN, Suplotova LA, Nosikov VV. The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel. *Acta Diabetologica*. 2011; 48:227–35. [PubMed: 21611789]
43. Pascoe L, Tura A, Patel SK, Ibrahim IM, Ferrannini E, Zeggini E, et al. Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. *Diabetes*. 2007; 56:3101–4. [PubMed: 17804762]
44. Ryu J, Lee C. Association of glycosylated hemoglobin with the gene encoding CDKAL1 in the Korean Association Resource (KARE) study. *Human mutation*. Apr.2012 33:655–9. [PubMed: 22290723]
45. Miyaki K, Oo T, Song Y, Lwin H, Tomita Y, Hoshino H, et al. Association of a cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1) polymorphism with elevated hemoglobin A_{1c} levels and the prevalence of metabolic syndrome in Japanese men: interaction with dietary energy intake. *American journal of epidemiology*. Nov 1.2010 172:985–91. [PubMed: 20847106]
46. Bort R, Martinez-Barbera JP, Beddington RS, Zaret KS. Hex homeobox gene-dependent tissue positioning is required for organogenesis of the ventral pancreas. *Development*. Feb.2004 131:797–806. [PubMed: 14736744]
47. Pascoe L, Tura A, Patel SK, Ibrahim IM, Ferrannini E, Zeggini E, et al. Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. *Diabetes*. Dec.2007 56:3101–4. [PubMed: 17804762]
48. Lin P-I, Vance JM, Pericak-Vance MA, Martin ER. No Gene Is an Island: The Flip-Flop Phenomenon. *The American Journal of Human Genetics*. 2007; 80:531–8.

49. Hu C, Zhang R, Wang C, Yu W, Lu J, Ma X, et al. Effects of GCK, GCKR, G6PC2 and MTNR1B variants on glucose metabolism and insulin secretion. *PloS one*. Jan.2010 5:e11761. [PubMed: 20668700]
50. Langenberg C, Pascoe L, Mari A, Tura A, Laakso M, Frayling T, et al. Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response. *Diabetologia*. 2009; 52:1537–42. [PubMed: 19455304]
51. Lyssenko V, Nagorny CLF, Erdos MR, Wierup N, Jonsson A, Spégel, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. *Nature Genetics*. 2009; 41:82–8. [PubMed: 19060908]
52. Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. *Sleep Medicine*. 2007; 3(8 Suppl):34–42. [PubMed: 18032103]
53. Marselli L, Trincavelli L, Santangelo C, Lupi R, Del Guerra S, Boggi U, et al. Function and expression of melatonin receptors on human pancreatic islets. *European journal of endocrinology European Federation of Endocrine Societies*. 2008; 151:273–9.
54. Sim X, Ong RT, Suo C, Tay WT, Liu J, Ng DP, et al. Transferability of type 2 diabetes implicated Loci in multi-ethnic cohorts from southeast Asia. *PLoS Genet*. Apr.2011 7:e1001363. [PubMed: 21490949]
55. Rong R, Hanson RL, Ortiz D, Wiedrich C, Kobes S, Knowler WC, et al. Association Analysis of Variation in/Near FTO, CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2, LOC387761, and CDKN2B With Type 2 Diabetes and Related Quantitative Traits in Pima Indians. *Diabetes*. 2009; 58:478–88. [PubMed: 19008344]
56. Soranzo N. Genetic determinants of variability in glycated hemoglobin (HbA(1c)) in humans: review of recent progress and prospects for use in diabetes care. *Current Diabetes Reports*. 2011; 11:562–9. [PubMed: 21975967]

Table 1

Descriptive Statistics (s.d.: standard deviation, * denotes statistically significant difference between males and females)

	Mean (s.d.)	Males (n=540)	Females (n=604)
Age	36.85 (17.35)	35.97 (17.34)	37.63 (17.33)
BMI (kg/m ²) *	27.40 (6.08)	25.93 (4.82)	28.7 (6.76)
Fasting glucose (mg/dL) *	93.14 (10.98)	94.30 (11.20)	92.10 (10.69)
HbA _{1c} (%)	5.46 (0.39)	5.49 (0.35)	5.43 (0.42)
Fasting insulin (mU/L) *	14.62 (8.08)	13.49 (7.33)	15.58 (8.55)
HOMA-IR *	3.43 (2.27)	3.21 (2.21)	3.62 (2.30)
HOMA-B *	189.8(117.7)	167.1 (96.7)	209.0 (130.0)

Table 2

T2D risk SNPs, nearest gene, and allele frequencies.

SNP	Gene	Risk allele	Risk allele frequency in sample	Risk allele frequency in reference populations				
				YRI	CEU	CHB	JPT	MXL
rs4607103	<i>ADAMTS9</i>	C	0.60	0.69	0.79	0.57	0.60	0.67
rs4402960	<i>IGF2BP2</i>	T	0.28	0.53	0.31	0.27	0.33	0.21
rs7754840	<i>CDKAL1</i>	C	0.44	0.68	0.32	0.43	0.41	0.30
rs864745	<i>JAZF1</i>	T	0.60	0.78	0.49	0.77	0.82	0.64
rs13266634	<i>SLC30A8</i>	C	0.61	0.93	0.76	0.55	0.55	0.78
rs10811661	<i>CDKN2A</i>	T	0.79	0.97	0.82	0.58	0.54	0.87
rs12779790	<i>CDC123</i>	G	0.11	0.11	0.25	0.19	0.11	0.12
rs5015480	<i>HHEX</i>	C	0.35	0.62	0.57	0.20	0.19	0.51
rs7901695	<i>TCF7L2</i>	C	0.08	0.40	0.34	0.03	0.03	0.24
rs2237892	<i>KCNQ1</i>	C	0.59	0.90	0.92	0.65	0.62	0.76
rs5215	<i>KCNJ11</i>	C	0.40	0.02	0.37	0.38	0.35	0.42
rs7961581	<i>TSPAN8</i>	C	0.08	0.18	0.26	0.18	0.24	0.14
rs10830963	<i>MTNR1B</i>	G	0.32	0.03	0.26	0.45	0.46	0.22
rs9939609	<i>FTO</i>	A	0.16	0.50	0.46	0.15	0.19	0.23

Table 3: Association of T2D SNPs with T2D-related quantitative traits with and without adjustment for BMI. Reference allele refers to the risk allele as determined by GWAS in Europeans.

SNP	Gene	Ref. & risk Allele	FG	FI	HbA _{1c}	FG & HbA _{1c}	HOMA-IR	HOMA-B
rs4607103	<i>ADAMTS9</i>	C	-0.091, p=0.57	0.21, p=0.25	0.06, p=0.75	6×10^{-5} , p=1	0.01, p=0.38	0.03, p=0.16
	w/out BMI		-0.096, p=0.56	0.28, p=0.17	0.03, p=0.88	-0.0003, p=0.99	0.02, p=0.27	0.03, p=0.11
rs4402960	<i>IGF2BP2</i>	T	0.429, p=0.021	0.1, p=0.65	-0.09, p=0.68	0.04, p=0.22	0.03, p=0.13	-0.03, p=0.25
	w/out BMI		0.36, p=0.059	-0.07, p=0.78	-0.19, p=0.42	0.03, p=0.49	0.01, p=0.51	-0.04, p=0.12
rs7754840	<i>CDKAL1</i>	C	0.222, p=0.18	0.13, p=0.48	0.68, p=0.00091	0.08, p=0.012	0.01, p=0.37	-0.01, p=0.59
	w/out BMI		0.203, p=0.23	0.14, p=0.52	0.72, p=0.00074	0.08, p=0.012	0.02, p=0.4	-0.01, p=0.62
rs864745	<i>JAZF1</i>	T	0.179, p=0.28	0.06, p=0.74	0.08, p=0.7	0.03, p=0.41	0.01, p=0.59	-0.01, p=0.49
	w/out BMI		0.204, p=0.23	0.05, p=0.82	0.05, p=0.8	0.02, p=0.46	0.01, p=0.67	-0.02, p=0.45
rs13266634	<i>SLC30A8</i>	C	0.123, p=0.45	0.16, p=0.4	0.05, p=0.81	0.02, p=0.51	0.01, p=0.66	0.02, p=0.34
	w/out BMI		0.133, p=0.43	0.23, p=0.27	0.09, p=0.65	0.03, p=0.39	0.01, p=0.47	0.02, p=0.28
rs10811661	<i>CDKN2A</i>	T	-0.067, p=0.73	-0.25, p=0.27	0.04, p=0.89	0.01, p=0.77	-0.01, p=0.63	-0.03, p=0.32
	w/out BMI		-0.07, p=0.73	-0.21, p=0.41	0.04, p=0.88	0.02, p=0.7	-0.01, p=0.8	-0.02, p=0.37
rs12779790	<i>CDC123</i>	G	0.374, p=0.17	0.21, p=0.49	0.05, p=0.87	0.07, p=0.21	0.03, p=0.32	-0.005, p=0.9
	w/out BMI		0.341, p=0.22	0.07, p=0.84	0.07, p=0.85	0.07, p=0.23	0.02, p=0.58	-0.01, p=0.7
rs5015480	<i>HHEX</i>	C	-0.496, p=0.0043	0.21, p=0.29	-0.61, p=0.0046	-0.12, p=0.00046	-0.01, p=0.49	0.07, p=0.0014
	w/out BMI		-0.395, p=0.027	0.35, p=0.11	-0.49, p=0.03	-0.1, p=0.0066	0.002, p=0.91	0.08, p=0.00064
rs7901695	<i>TCF7L2</i>	C	-0.263, p=0.42	0.28, p=0.47	-0.69, p=0.094	-0.1, p=0.11	0.004, p=0.9	0.04, p=0.34
	w/out BMI		-0.325, p=0.33	0.21, p=0.62	-0.71, p=0.097	-0.11, p=0.1	-0.001, p=0.98	0.04, p=0.41
rs2237897	<i>KCNQ1</i>	C	0.222, p=0.19	0.16, p=0.45	-0.15, p=0.5	0.03, p=0.39	0.02, p=0.23	-0.02, p=0.41
	w/out BMI		0.344, p=0.066	0.05, p=0.81	-0.2, p=0.4	0.02, p=0.63	0.01, p=0.51	-0.02, p=0.32
rs5215	<i>KCNJ11</i>	C	0.0425, p=0.8	-0.25, p=0.21	0.15, p=0.49	0.01, p=0.69	-0.01, p=0.5	-0.02, p=0.28
	w/out BMI		-0.043, p=0.8	-0.41, p=0.056	0.02, p=0.92	-0.01, p=0.85	-0.03, p=0.17	-0.03, p=0.13
rs10830963	<i>MTNR1B</i>	G	0.4234, p=0.018	-0.3, p=0.15	0.27, p=0.23	0.06, p=0.073	0.004, p=0.84	-0.06, p=0.0064
	w/out BMI		0.431, p=0.018	-0.41, p=0.073	0.15, p=0.51	0.05, p=0.19	-0.005, p=0.8	-0.07, p=0.0029
rs7961581	<i>TSPAN8</i>	C	-0.00083, p=1	-0.23, p=0.5	0.05, p=0.9	-0.01, p=0.82	-0.01, p=0.63	-0.02, p=0.65
	w/out BMI		0.077, p=0.81	-0.14, p=0.71	-0.03, p=0.94	-0.01, p=0.82	-0.01, p=0.84	-0.01, p=0.81
rs9939609	<i>FTO</i>	A	-0.272, p=0.22	8×10^{-5} , p=1	-0.04, p=0.88	-0.03, p=0.48	-0.01, p=0.7	0.03, p=0.33
	w/out BMI		-0.145, p=0.52	0.35, p=0.21	0.06, p=0.84	-0.002, p=0.96	0.02, p=0.4	0.05, p=0.086

Table 4

Association of T2D genetic risk score (GRS) with T2D-related quantitative traits. (p-values shown; statistically significant associations shown in bold)

	FG	FI	HbA _{1c}	FG & HbA _{1c}	HOMA-IR	HOMA-B
GRS	0.17	0.50	0.42	0.21	0.238	0.7
GRS without <i>HHEX</i>	0.021	0.75	0.08	0.014	0.148	0.15